Activist Mark Hannay explains what the bill means for people living with HIV and how it will shape the 2020 election debate.
Drug pricing expert Tim Horn helps us make sense of the administration's future plans for the Medicare Part D and 340B programs.
In order to adequately address the HIV epidemic in the United States, two advocates argue that the high cost of antiretroviral drugs must be addressed.
With the House of Representatives Now in Democratic Hands, Here's What the Birddog Nation Activists Have Planned for Health Care in 2019
The activists have big plans for using their techniques to pressure the new Congress into inching toward universal health care in the years ahead.
Advocates for single-payer health care in New York protested at a conference for executives from the state's various private insurers, which the New York Health Act (NYHA), the single-payer bill in question, would put out of business.
Congress is divided, and all sorts of new possibilities are in play. What does it all mean for folks living with HIV, and for health care generally? We chatted with veteran activist Mark Hannay to find out.
Despite Protections for People With HIV, Advocates Express Concern With State Medicaid Work and Reporting Waivers
The Trump administration's preconditions for Medicaid coverage are a major shift in how the program has functioned since its inception in 1965.
Virginia could possibly serve as a case study in developing innovative strategies to improve health care access in its use of an open "drug formulary."
Patients' rights activists and health industry's big players are usually at odds with each other, but now they are championing similar tactics to tame prescription drug prices.
Despite multiple lawsuits, the Trump administration's push for implementation of Medicaid work requirements continues to move forward.